A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This was a randomized, open-label, active-controlled, dose-finding, phase II study to evaluate the efficacy and safety of 2 doses of F-627 compared to Filgrastim in women with breast cancer receiving myelotoxic chemotherapy. Subjects would be randomized to one of three arms, which were 10 mg/dose of F-627, 20 mg/dose of F-627 or Filgrastim, in an equal ratio.
Epistemonikos ID: 9549011a7cf3d4db643ac9636d8dc2b0f023461a
First added on: May 12, 2024